RxDoctor Payments Data

Michael Kennelly

Cardiovascular Disease · du Bois, PANPI 1508573353

Payments from drug & device makers

$1,079in general payments, 2019–2025

Across 105 payments — averaging $10.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$473
  • E.r. Squibb & Sons, L.L.C.$150
  • Pfizer$149
  • Actelion Pharmaceuticals US, Inc.$125
  • Kiniksa Pharmaceuticals International, PLC$53
  • Merck$31
  • plus $98 from 4 others

What the payments were for

  • Food & beverage$1,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,079 in reported general payments places this provider in the 40th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$56,721
Medicare patients
404
Services billed
755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban279$242,633
EntrestoSacubitril/Valsartan190$202,945
JardianceEmpagliflozin110$101,545
XareltoRivaroxaban61$40,142
BrilintaTicagrelor24$20,141
Repatha SyringeEvolocumab12$11,647
FarxigaDapagliflozin Propanediol19$11,366
Ranolazine ErRanolazine130$8,823
Repatha SureclickEvolocumab13$7,063
Metoprolol Succinate376$6,179
Carvedilol262$2,826
Atorvastatin Calcium175$2,349
Valsartan103$2,324
Isosorbide Mononitrate ErIsosorbide Mononitrate116$2,104
Bumetanide55$1,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$242,633279 claims
AstraZenecaBrilinta, Farxiga$31$31,50743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →